Skip to main content
. 2023 Apr 15;24(8):7336. doi: 10.3390/ijms24087336

Figure 3.

Figure 3

Substituted SOX (4a) is a potent inhibitor of the tyrosine kinase domain of the EGFR (PDB ID:1M17). (A) Binding pattern of the substituted SOX (4a) against human EGFR (∆G: −6.55 Kcal/mol); (B) Binding pattern of doxorubicin against human CD44 (∆G: −10.11 Kcal/mol). Subpanels (a) represent the interaction of 4a and doxorubicin inside the active pocket of the target protein (represented as a red surface). Subpanels (b) show the 2D image of the interacting residues of the EGFR with our drugs.